In light of our current findings, with the knockdown of S1P2 having no impact on AML cell viability (Fig. 5B), it is most likely that our previous findings with JTE-013 were due to SK1 inhibition and altered sphingolipid metabolism, rather than due to antagonism of S1P2. This evidence concerns the gene S1PR2 and acute myeloid leukemia.